TY - JOUR
T1 - Prevalence and Risk Factors for Fatigue in Adults With Inflammatory Bowel Disease
T2 - A Systematic Review With Meta-Analysis
AU - D'Silva, Adrijana
AU - Fox, Danielle E.
AU - Nasser, Yasmin
AU - Vallance, Jeff K.
AU - Quinn, Robert R.
AU - Ronksley, Paul E.
AU - Raman, Maitreyi
N1 - Funding Information:
The authors thank Diane Lorenzetti and Heather Ganshorn for their guidance and assistance with the search strategy. They also thank Linda Dorrestein and Ping Liu for their helpful role in study selection and data extraction for articles that were not in the English language.
Publisher Copyright:
© 2022 AGA Institute
PY - 2022/5
Y1 - 2022/5
N2 - Background and Aims: Inflammatory bowel disease (IBD) is a chronic relapsing and remitting disease with high morbidity, substantial health care costs, and increasing incidence. Fatigue is one of the most common symptoms that impacts quality of life and is a leading concern for patients with IBD. The aim of this study was to determine the global prevalence, risk factors, and impact of fatigue in adults with IBD. Methods: A systematic review and meta-analysis was conducted. Data were retrieved from Medline, Embase, CINAHL, and PsycINFO from database inception to October 2019. A pooled prevalence of fatigue was calculated using a random-effects model. Stratified meta-analyses explored sources of between-study heterogeneity. Study quality was assessed using an adapted checklist from Downs and Black. Results: The search yielded 4524 studies, of which 20 studies were included in the systematic review and meta-analysis. Overall, the studies were of good quality. The pooled prevalence of fatigue was 47% (95% confidence interval, 41%–54%), though between-study heterogeneity was high (I2 = 98%). Fatigue prevalence varied significantly by the definition of fatigue (chronic: 28%; high: 48%; P < .01) and disease status (active disease: 72%; remission: 47%; P < .01). Sleep disturbance, anxiety, depression, and anemia were the most commonly reported fatigue-related risk factors. Conclusions: The prevalence of fatigue in adults with IBD is high, emphasizing the importance of additional efforts to manage fatigue to improve the care and quality of life for patients with IBD.
AB - Background and Aims: Inflammatory bowel disease (IBD) is a chronic relapsing and remitting disease with high morbidity, substantial health care costs, and increasing incidence. Fatigue is one of the most common symptoms that impacts quality of life and is a leading concern for patients with IBD. The aim of this study was to determine the global prevalence, risk factors, and impact of fatigue in adults with IBD. Methods: A systematic review and meta-analysis was conducted. Data were retrieved from Medline, Embase, CINAHL, and PsycINFO from database inception to October 2019. A pooled prevalence of fatigue was calculated using a random-effects model. Stratified meta-analyses explored sources of between-study heterogeneity. Study quality was assessed using an adapted checklist from Downs and Black. Results: The search yielded 4524 studies, of which 20 studies were included in the systematic review and meta-analysis. Overall, the studies were of good quality. The pooled prevalence of fatigue was 47% (95% confidence interval, 41%–54%), though between-study heterogeneity was high (I2 = 98%). Fatigue prevalence varied significantly by the definition of fatigue (chronic: 28%; high: 48%; P < .01) and disease status (active disease: 72%; remission: 47%; P < .01). Sleep disturbance, anxiety, depression, and anemia were the most commonly reported fatigue-related risk factors. Conclusions: The prevalence of fatigue in adults with IBD is high, emphasizing the importance of additional efforts to manage fatigue to improve the care and quality of life for patients with IBD.
KW - Fatigue
KW - Inflammatory Bowel Disease
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85114680804&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2021.06.034
DO - 10.1016/j.cgh.2021.06.034
M3 - Review article
C2 - 34216824
AN - SCOPUS:85114680804
SN - 1542-3565
VL - 20
SP - 995-1009.e7
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 5
ER -